Based on the expression of Granzymes, Perforin, Granulysin and other cytolysis-associated markers, CD4+ CTL have been detected in bladder cancer, colorectal cancer, lung cancer, melanoma, and other tumors (146, 188–194). This evidence concerns the gene PRF1 and urinary bladder carcinoma.